Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Neoplasms 4Nasopharyngeal Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Head and Neck Neoplasms 2Stomach Neoplasms 1Resectable Pancreatic Cancer 1Penile Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Glioma 1Glioblastoma 1Esophageal 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Advanced and/or Metastatic Solid Tumours 1Advanced Esophageal 1Adenocarcinoma 1

Interventions

nimotuzumab 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Esophageal × nimotuzumab × Clear all
NCT02591784 2022-03-17

Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer

Biotech Pharmaceutical Co., Ltd.

Phase 2 Completed
42 enrolled
Gastrointestinal

Esophageal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡